Newswire

Newswire

Convidecia™ Phase III Results Published in The Lancet

96.0% effective against severe disease 14 days post-vaccination for population aged 18 and above. Single-dose vaccine received approvals in at least 10 markets including China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia. TIANJIN, China, Dec….

Triterras Provides Update on Nasdaq Listing

SINGAPORE, Dec. 23, 2023 (GLOBE NEWSWIRE) — Triterras Inc. (NasdaqGM: TRIT, TRITW) (“Triterras” or the “Company”), a leading fintech company focused on trade and trade finance, is providing an update on Nasdaq’s December 10, 2023 determination to delist the Company…